Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

PBS. 2021; 11(1): 1-7


Retrospective Analysis of Patients with Disruptive Mood Dysregulation Disorder and Psychopharmacologic Treatment Preferences

Zehra Topal, Yusuf Ozturk, Ali Evren Tufan, Nuran Demir, Bengi Semerci.




Abstract

Background: DMDD is a new diagnosis listed in the DSM-5. Here, we aimed to present a retrospective analysis of cases with probable DMDD and their psychopharmacological treatment characteristics.
Methods: 200 patients complaining of “irritability” and “temper tantrums” were evaluated retrospectively. To differentiate those with probable DMDD; Young Mania Rating Scale, Children’s Depression Inventory, Screen for Anxiety and Related Disorders, Atilla Turgay Scale for DSM-IV-TR Disruptive Behavior Disorders scores were used.
Results: 99 patients were found to fulfill criteria for DMDD. 85 patients (87.6 %) were prescribed drugs. Most common drugs were risperidone, methylphenidate, atomoxetine, OROS methylphenidate, sertraline and fluoxetine in descending order. Females are more frequently prescribed SSRIs while males are prescribed other drugs
Conclusion: Because there is no treatment guidelines for DMDD yet, pharmacological treatment often targets core symptoms such as chronic irritability and outbursts of anger. İn this study female patients were more frequently prescribed fluoxetine while males prescribed more frequently other drugs such as methylphenidate and risperidone. Clinicians might determine more internalizing problems on female children and externalizing problems on males.

Key words: Disruptive Mood Dysregulation Disorder, irritability, temper tantrums, treatment






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.